Gilead Signs Triple Therapy Deal for HIV
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 7 (Table of Contents)
Published: 30 Jul-2009
DOI: 10.3833/pdr.v2009.i7.1141 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Gilead Sciences entered into an agreement with Tibotec Pharmaceuticals for the development and commercialization of a new once-daily fixed-dose antiretroviral regimen containing Gilead's Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec's investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC 278 (rilpivirine hydrochloride)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS